The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
Yawn. So many uninvested shorters here today. I've not read this many desperate posts for a while. They seem intensely triggered. Tight Shorts? IMHO!
Let them get it all out, I think I'll come back in a week...
Good summary Tommy Fruits (although it's wasted on the majority of posters here today who seem to have the day off trading skoool !!! / kindergarten).
HNY to all.
Lol Docdaneeka, you really are more anti-knowledge, anti-research and anti-fact than I have given you credit for.
Correct, I'm not worried at all about yet another vaccine. They can barely push the elderly uptake past 40% flu vaccination in this country, never mind worldwide. And that's after annual pushes over decades.
As for RSV, it's predominently paediatric patients that really need a vaccine given it affects many newborns and toddlers ill-equipped to deal with it, so I'm glad they will benefit. Paediatric prophylaxis is not a market we're targeting.
Sure,
Forgot the *there is little data* "that it provides additional benefit when added to inhaled corticosteroid or triple therapy and, therefore, when this drug is best utilized in clinical practice."
And as we know, data is everything.
Ah behold, tis the first "Too late to the party" of the New Year! What fun.
The experts however, when commenting on Ensifentrine, actually report that although generally well tolerated, it provides additional benefit when added to inhaled corticosteroid or triple therapy and, therefore, when this drug is best utilized in clinical practice. Certainly, the drug represents a useful therapeutic option, but further clinical studies are needed to be able to correctly position Ensifentrine in the context of regular COPD treatment. SNG001 is also targeting multiple diseases not just COPD, something Brighty and MyIPA may not have forgotten...?
More of a deflated New Years Balloon, than an actual threat, I'd say.
The company is still clearly undervalued for a blockbuster opportunity. I'm looking forward to news from the company soon.
"Every good laboratory consists of first rate men working in great harmony to insure the progress of science; but down at the end of the hall is an unsociable, wrong-headed fellow working on unprofitable lines, and in his hands lies the hope of discovery".
Also Ernest Rutherford
Watford wasn't the first mis-step for the underpowered NGHT management team. Adverse economic conditions and train strikes can only be blamed for so long. Unimpressive.
"Wrong again".....
Do elaborate TP?
Swing traders readying themselves for the start of a new year.
Keep digging and slinging mud DocD. I note that barely a day goes by without you wrongly accusing me of some ramping nonsense or other. The more I ignore, the more desperate your rants seem to become? Sitting in tight shorts at the end of the year, it must feel rather uncomfortable....
Very Excellent news.
Trade that, Prof & Co!
Thanks @TommyD_19 for that link. Isn't it notable that of the 910 spinouts that were enabled by UKRI funding, the UKRI chose to highlight just 3 of those in their 'Highlights' section of their report? 3, out of 910. Synairgen is one of those three.
"Spinout develops faster diagnoses and alternative treatments for lung infections Synairgen, a Southampton-based spinout company with 24 employees, is developing an inhaled interferon beta candidate for severe viral lung infections,
including asthma, COPD and COVID-19. Engaging with Southampton General Hospital, Synairgen’s COVID-19 trial reduced the waiting time of a point-of-care test used to recruit patients to within one hour, a dramatic reduction from one day, and had positive impacts on patient flow. Since its launch, Synairgen has raised more than £129 million to fund clinical trials, has increased its market capitalisation tenfold to £300 million, and has received £10 million through licensing. MRC-funded research has supported the discovery science underpinning inhaled interferon beta therapy
for nearly five decades, identifying many of the disease mechanisms involved."
As you said Patagucci, the need for the drug has certainly not gone away:
https://www.independent.co.uk/news/health/hospitals-flu-nhs-england-danger-b2460096.html
“The rise in winter viruses and staff sickness suggests that the pressure on health services is only going to continue to mount as we get deeper into winter."
Https://metro.co.uk/2023/11/30/denmark-sees-surge-white-lung-syndrome-demands-chinese-data-19906576/
It's interesting that Ethris signed a deal in 2017 with Aztra Zeneca (your fav BP Doc!). The deal was to last 5 years. Oddly, no mention of AZ anywhere about them wishing to extend that deal to develop MrNA tech with Ethris in the recent announcement below? In fact, not only has AZ seem to have vanished, but Ethris secured their own funding in early 2022 by raising$26.3 Million (€23.3 Million) in a Series B financing round led by Laureus Capital. They had to give a seat on the BOD to a n LC Exec as well. I guess they needed the cash with AZ gone? The proceeds of that funding were to advance the company’s lead programs ETH47 - a broad anti-viral immune modulator. Did AZ decide after 5 years to step away from the yet-to-be-clinically-tested Ethris drug for reasons better known to AZ...? It seem strange that they are no longer part of a collaboration? Perhaps it doesn't work as well as they hoped? Maybe a P1, and subsequent trials if there are some, will reveal more?
Let's try that again:
There's an excellent article here on what MrNA technology is good for, and more precisely what is is not. Well worth a read if you've not had a chance to delve into it much: https://www.science.org/content/blog-post/what-mrna-good-and-what-it-maybe-isn-t
It would be interesting to know what Tommy's thoughts are on this, seeing as he posted it.
There's an excellent article here on what MrNA technology is good for, and more precisely what is is not. Well worth a read if you've
It would be interesting to know what Tommy's thoughts are on this, seeing as he posted it.
I thought your dad worked in pharma XV?
"doom-laden nonsense"? As is usually the case, I expected you'd be triggered again DocD by simple factual media reporting. As for Earl's spurious nonsense, anyone with half a brain knows his game, your choice to engage, not a tactic I waste energy on. If throwing shade and your usually muckery in my direction gives you kicks and kudos, I won't rob you of that warm fuzzy feeling. You seem to need it.
Ref the news alignment, It is what it is - you can't alter reality.
As for the "I don't really know how t (p&d) works" comment, .... You really think anyone (other than your phony cohort of multiple personality disordered accounts) believes that? Maybe they can explain it to you. I'm crying, Lol....